TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
TransCode Therapeutics presented Phase 1a clinical data for TTX-MC138 in a poster (1025P) at the ESMO Congress 2026 in Madrid. The study met its primary safety endpoint with no dose-limiting toxicities across four dose levels from 0.8 to 4.8 mg/kg, and showed dose-dependent plasma exposure plus disease stabilization and extended progression-free intervals in a subset of heavily pretreated patients with advanced solid tumors.
Key figures
- Drug Name
- TTX-MC138
- Phase Of Trial
- Phase 1a
- Dose levels
- 0.8 mg/kg to 4.8 mg/kg
- Dosing interval
- once every 28 days
- Dose limiting toxicities
- 0
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.